(Reuters) - Advanced Medical Optics Chief Executive James Mazzo, responding to a critical letter from ValueAct, said he was "surprised and disappointed" by ValueAct's opposition to the $4.23 billion hostile bid for Bausch & Lomb.
Mazzo said this was "especially hard to understand given
Read more at Reuters.com Government Filings News
Mazzo said this was "especially hard to understand given
Read more at Reuters.com Government Filings News
No comments:
Post a Comment